Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Innate Pharma (IPHA)
NASDAQ:IPHA
Holding IPHA?
Track your performance easily
IPHA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.44 - $3.15
Previous Close$1.44
Volume20.23K
Average Volume (3M)8.80K
Market Cap
$122.91M
Enterprise Value$75.09M
Total Cash (Recent Filing)€92.46M
Total Debt (Recent Filing)€47.54M
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Sep 12, 2024EPS Estimate
-$0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding80,453,282
10 Day Avg. Volume6,374
30 Day Avg. Volume8,805
Standard Deviation0.18
R-Squared0.01
Alpha-0.00873
Financial Highlights & Ratios
Price to Book (P/B)2.21
Price to Sales (P/S)2433109.43
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.25Price Target Upside472.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Innate Pharma News
Ownership Overview
―
Insiders
0.11% Other Institutional Investors
99.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IPHA FAQ
What was Innate Pharma’s price range in the past 12 months?
Innate Pharma lowest stock price was $1.44 and its highest was $3.15 in the past 12 months.
What is Innate Pharma’s market cap?
Currently, no data Available
When is Innate Pharma’s upcoming earnings report date?
Innate Pharma’s upcoming earnings report date is Sep 12, 2024 which is 66 days ago.
How were Innate Pharma’s earnings last quarter?
Innate Pharma released its earnings results on Mar 21, 2024. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.436 by $0.306.
Is Innate Pharma overvalued?
According to Wall Street analysts Innate Pharma’s price is currently Undervalued.
Does Innate Pharma pay dividends?
Innate Pharma does not currently pay dividends.
What is Innate Pharma’s EPS estimate?
Innate Pharma’s EPS estimate is -$0.3.
How many shares outstanding does Innate Pharma have?
Innate Pharma has 80,967,410 shares outstanding.
What happened to Innate Pharma’s price movement after its last earnings report?
Innate Pharma reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.436. Following the earnings report the stock price went down -3.39%.
Which hedge fund is a major shareholder of Innate Pharma?
Currently, no hedge funds are holding shares in IPHA
---
Innate Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.46%
12-Months-Change
Fundamentals
Return on Equity
-78.33%
Trailing 12-Months
Asset Growth
-25.23%
Trailing 12-Months
Company Description
Innate Pharma
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies.
---
IPHA Company Deck
---
IPHA Earnings Call
Q2 2024
0:00 / 0:00
---
IPHA Stock 12 Month Forecast
Average Price Target
$8.25
▲(472.92% Upside)
Technical Analysis
Best Analysts Covering IPHA
1 Year
1 Year Success Rate
5/21 ratings generated profit
1 Year Average Return
-16.91%
reiterated a buy rating last month
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 23.81% of your transactions generating a profit, with an average return of -16.91% per trade.
---